302 related articles for article (PubMed ID: 11263172)
61. Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: a randomized clinical trial.
Sadeghi-Bazargani H; Ehdaeivand F; Arshi S; Eftekhar H; Sezavar H; Amanati L
Med Sci Monit; 2006 Oct; 12(10):CR420-5. PubMed ID: 17006401
[TBL] [Abstract][Full Text] [Related]
62. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
Sonalkar S; McClusky J; Hou MY; Borgatta L
Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
[TBL] [Abstract][Full Text] [Related]
63. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
64. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
65. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
66. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
Ziaei S; Ninavaei M; Faghihzadeh S
Acta Obstet Gynecol Scand; 2004 Oct; 83(10):909-11. PubMed ID: 15453884
[TBL] [Abstract][Full Text] [Related]
67. Injectable contraceptives.
Toppozada M
Contracept Deliv Syst; 1982 Apr; 3(2):161-70. PubMed ID: 12338171
[TBL] [Abstract][Full Text] [Related]
68. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
69. Comparative contraceptive experience with three-month and six-month medroxyprogesterone acetate regimens.
Rall HJ; van Niekerk WA; Engelbrecht BH; van Schalkwyk DJ
J Reprod Med; 1977 Feb; 18(2):55-60. PubMed ID: 833802
[TBL] [Abstract][Full Text] [Related]
70. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
71. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
[TBL] [Abstract][Full Text] [Related]
72. Introduction of cyclofem once-a-month injectable contraceptive in Mexico.
Garza-Flores J; Moraks del Olmo A; Fuziwara JL; Figueroa JG; Alonso A; Monroy J; Perez M; Urbina-Fuentes M; Guevara SJ; Cedeno E; Barrios R; Ferman JJ; Medina LM; Velazquez E; Perez-Palacios G
Contraception; 1998 Jul; 58(1):7-12. PubMed ID: 9743890
[TBL] [Abstract][Full Text] [Related]
73. Depot-medroxyprogesterone acetate contraception use among Salvadoran women: an in-depth analysis of attitudes and experiences.
Cremer M; Ditzian L; April A; Peralta E; Klausner D; Podolsky R; Dierking E
J Womens Health (Larchmt); 2011 Nov; 20(11):1751-6. PubMed ID: 21823919
[TBL] [Abstract][Full Text] [Related]
74. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
[TBL] [Abstract][Full Text] [Related]
75. Injectable contraception: the USA perspective.
Kaunitz AM
IPPF Med Bull; 1992 Dec; 26(6):1-3. PubMed ID: 12346920
[TBL] [Abstract][Full Text] [Related]
76. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
[TBL] [Abstract][Full Text] [Related]
77. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
78. Progestin-only contraception: injectables and implants.
Jacobstein R; Polis CB
Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):795-806. PubMed ID: 24996766
[TBL] [Abstract][Full Text] [Related]
79. Use of depot medroxyprogesterone acetate in Thai adolescents.
Chotnopparatpattara P; Taneepanichskul S
Contraception; 2000 Sep; 62(3):137-40. PubMed ID: 11124361
[TBL] [Abstract][Full Text] [Related]
80. Injectable contraceptives: underused and undervalued?
Parker C
Prof Care Mother Child; 1997; 7(4):95-7. PubMed ID: 9348967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
